CIMETIDINE

Search structure


Trade Names:	CIMETIDINE TAGAMET TAGAMET HB TAGAMET HB 200
Synonyms:	ACID-EZE ACILOC ACINIL ACITAK 200 ACITAK 400 ACITAK 800 BRUMETADINA BRUMETIDINA CIMAL CIMETIDINA CIMETIDINUM DYSPAMET GALENAMET GASTROMET KENTAMET NSC-335308 PEPTIMAX 200 PEPTIMAX 400 PEPTIMAX 800 SKF-92334 STOMEDINE TAGADINE TAGAMET TAGAMET 100 TAGAMET HB TAGAMET HB 200 ULCEDIN ULCIMET ULCOMEDINA ULTEC VALMAGEN ZITA
Status:	Approved (1977)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	A02BA01
UNII:	80061L1WGD

Structure


InChI Key	AQIXAKUUQRKLND-UHFFFAOYSA-N
Smile	CN/C(=N/CCSCc1nc[nH]c1C)NC#N
InChI	InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H16N6S
Molecular Weight	252.35
AlogP	0.6
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	5.0
Polar Surface Area	88.89
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	17.0

Pharmacology

Action	Mechanism of Action	Reference
ANTAGONIST	Histamine H2 receptor antagonist

	Primary Target
H₂ receptor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6	-	-	-	77000	-
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4	-	15000-1000000	-	-	-
Enzyme Hydrolase	-	820	-	-	-4.484-5.577
Enzyme Oxidoreductase	-	-	-	155000	-
Enzyme Transferase	-	-	-	-	17.13
Enzyme	-	15000-1000000	-	155000	0-1
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-42.18--3.9
Ion channel Voltage-gated ion channel Voltage-gated sodium channel	-	-	-	-	0-4.1
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Acetylcholine receptor	-	-	-	-	2-2
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Histamine receptor	-	140-5523	263.03-1000	70-5431	43-43
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	24.8-96.42
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	149000	-	9400-198000	4.13-8.1
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC47 family of multidrug and toxin extrusion transporters	-	1200-5700	-	-	-
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	-	-	-	4
Transporter Primary active transporter P-type ATPase Hydrogen potassium ATPase	-	820	-	-	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Dermatitis, Atopic	3	D003876	ClinicalTrials
Gastrointestinal Hemorrhage	3	D006471	ClinicalTrials
Hemorrhage	3	D006470	ClinicalTrials
Ulcer	3	D014456	ClinicalTrials
Breast Carcinoma In Situ	2	D000071960	ClinicalTrials
Endometrial Neoplasms	2	D016889	ClinicalTrials
Breast Neoplasms	2	D001943	ClinicalTrials
Protoporphyria, Erythropoietic	2	D046351	ClinicalTrials
Breast Neoplasms	2	D001943	ClinicalTrials
Amyotrophic Lateral Sclerosis	1	D000690	ClinicalTrials
Anxiety Disorders	1	D001008	ClinicalTrials
Infections	1	D007239	ClinicalTrials
Pulmonary Disease, Chronic Obstructive	1	D029424	ClinicalTrials

Related Entries

Salt

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Nervous system disorders Headache	3.1
Gastrointestinal disorders Diarrhoea	1.8
General disorders and administration site conditions Asthenia	1.7
General disorders and administration site conditions Fatigue	1.7
Cardiac disorders Dizziness	1.3
Nervous system disorders Somnolence	1.3
Skin and subcutaneous tissue disorders Dermatitis	1.2
Skin and subcutaneous tissue disorders Rash	1.2
Gastrointestinal disorders Constipation	1.0

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Cardiac disorders	13.94
General disorders and administration site conditions	13.51
Gastrointestinal disorders	10.55
Psychiatric disorders	9.23
Nervous system disorders	8.99
Investigations	7.91
Injury, poisoning and procedural complications	6.87
Respiratory, thoracic and mediastinal disorders	4.47
Metabolism and nutrition disorders	3.77
Vascular disorders	3.53
Immune system disorders	3.48
Skin and subcutaneous tissue disorders	3.44

Cross References

Resources	Reference
CAS NUMBER	51481-61-9
ChEBI	3699
ChEMBL	CHEMBL30
DrugBank	DB00501
DrugCentral	645
EPA CompTox	DTXSID4020329
FDA SRS	80061L1WGD
Human Metabolome Database	HMDB14644
Guide to Pharmacology	1231
KEGG	C06952
PharmGKB	PA449001
PubChem	2756
SureChEMBL	SCHEMBL1093
ZINC	ZINC000018115268

CONTENTS